Antibody-Drug Conjugates Containing Payloads from Marine Origin

Area of Science:

• Oncology
• Medicinal Chemistry
• Pharmacology

Background:

• Antibody-drug conjugates (ADCs) represent a significant advancement in cancer therapeutics.
• ADCs combine the specificity of antibodies with the potency of cytotoxic drugs, minimizing off-target toxicity.
• The development of ADCs involves expertise in biology, biochemistry, and organic chemistry.

Purpose of the Study:

• To review the molecular and biological diversity of ADCs.
• To focus on ADCs that incorporate marine-derived cytotoxic drugs as payloads.
• To explore the synthetic and therapeutic potential of marine natural products in ADC development.

Main Methods:

• Literature review of existing ADCs and their payloads.
• Analysis of the structural and biological properties of marine-derived cytotoxic compounds.
• Examination of synthetic strategies for developing marine-based ADCs.

Main Results:

• Marine natural products exhibit remarkable structural complexity and potent biological activity, making them attractive ADC payloads.
• Several marine-derived compounds have been successfully integrated into ADC designs.
• The unique properties of marine payloads contribute to the high specificity and efficacy of ADCs.

Conclusions:

• ADCs containing marine cytotoxic drugs offer a promising therapeutic strategy for various cancers.
• The chemical synthesis and exploration of marine compounds are crucial for advancing ADC technology.
• Further research into marine-derived payloads will likely yield novel and effective cancer treatments.